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Background: Adoptive T cell therapy (ACT) has shown great promise in melanoma, with over 50 % response rate
in patients where autologous tumor-reactive tumor-infiltrating lymphocytes (TIL) can be cultured and expanded. A
major limitation of ACT is the inability to generate or expand autologous tumor-reactive TIL in 25–45 % of patients
tested. Methods that successfully identify tumors that are not suitable for TIL generation by standard methods
would eliminate the costs of fruitless expansion and enable these patients to receive alternate therapy immediately.
Methods: Multispectral fluorescent immunohistochemistry with a panel including CD3, CD8, FoxP3, CD163, PD-L1
was used to analyze the tumor microenvironment in 17 patients with melanoma among our 36-patient cohort to
predict successful TIL generation. Additionally, we compared tumor fragments and enzymatic digestion of tumor
samples for efficiency in generating tumor-reactive TIL.
Results: Tumor-reactive TIL were generated from 21/36 (58 %) of melanomas and for 12/13 (92 %) tumors where
both enzymatic and fragment methods were compared. TIL generation was successful in 10/13 enzymatic
preparations and in 10/13 fragment cultures; combination of both methods resulted in successful generation of
autologous tumor-reactive TIL in 12/13 patients. In 17 patients for whom tissue blocks were available, IHC analysis
identified that while the presence of CD8+ T cells alone was insufficient to predict successful TIL generation, the
CD8+ to FoxP3+ ratio was predictive with a positive-predictive value (PPV) of 91 % and negative-predictive value
(NPV) of 86 %. Incorporation of CD163+ macrophage numbers and CD8:PD-L1 ratio did not improve the PPV.
However, the NPV could be improved to 100 % by including the ratio of CD8+:PD-L1+ expressing cells.
Conclusion: This is the first study to apply 7-color multispectral immunohistochemistry to analyze the immune
environment of tumors from patients with melanoma. Assessment of the data using unsupervised hierarchical
clustering identified tumors from which we were unable to generate TIL. If substantiated, this immune profile could
be applied to select patients for TIL generation. Additionally, this biomarker profile may also indicate a pre-existing
immune response, and serve as a predictive biomarker of patients who will respond to checkpoint blockade. We
postulate that expanding the spectrum of inhibitory cells and molecules assessed using this technique could guide
combination immunotherapy treatments and improve response rates.
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ACT with autologous TIL has shown great promise
against metastatic melanoma, with response rates of up
to 50–70 % and complete responses of up to 20 % [1–3].
In patients with melanoma, 95 % of the complete
responders demonstrated a durable response for at least
5 years [1]. While the anti-tumor effect of ACT appears
to be primarily mediated by CD8+ effector T cells [3–5],
CD4+ T cells can also mediate tumor regression and
may play a critical role in maintaining long-term im-
munity and cure of patients [6, 7]. T cells used for ACT
are expanded from patients’ autologous tumors by
in vitro culture with high-dose interleukin 2. Cultured
TIL that recognize autologous tumor and secrete γ-
interferon are considered autologous tumor-reactive.
These cells are then cultured using a rapid expansion
protocol (REP) and adoptively transferred into patients
[5, 8–14]. A major limitation of adoptive T cell therapy
is the inability to generate or expand tumor-reactive
lymphocytes from many tumors. Autologous tumor-
reactive T cells can be produced from 50 to 75 % of mel-
anoma specimens, but success rates are much lower for
other cancers (0–20 % for renal, breast and colon cancers)
[15]. Identifying the reasons for failure of TIL isolation
and expansion is important if we are to make ACT
available to more patients with melanoma and other
tumor types. Additionally, recent reports suggest that the
response to checkpoint blockade agents such as anti-PD-1
and anti-PD-L1 is limited to patients with pre-existing im-
mune responses [16, 17]. Since the isolation of autologous
tumor-reactive TIL is potentially the best indicator that a
T cell response against a patient’s tumor cells exists, we
hypothesize that a pretreatment immunohistochemical
assessment that can predict the ability to generate autolo-
gous tumor-reactive T cells may also serve as a biomarker
to predict response to checkpoint blockade or other
immunotherapies.
Quantitative immunohistochemistry has been useful
for predicting response rates, treatment selection and
determining prognosis in many types of cancer [17, 18].
This is especially notable in colon cancer, where the type
and amount of tumor-infiltrating lymphocytes is highly
predictive of prognosis [19, 20]. Similar reports have
been made in melanoma, in which patients with high
CD8+ T cells are associated with better prognosis [21–23].
Recently, multiplex immunohistochemistry (IHC) has
emerged as an important tool for the analysis of the
tumor microenvironment. Compared to traditional sin-
gle color IHC methods, multiplex IHC methods are
more efficient and contain richer information sets for
both diagnostic and mechanistic studies [24, 25]. We
utilized a multispectral quantitative fluorescent immu-
nohistochemistry method, which allows simultaneous
detection of 7 markers, to explore potential suppressivemechanisms in the tumor microenvironment that may
prevent the generation of autologous tumor-reactive
TIL. The results not only demonstrate for the first time
the feasibility of this method in analyzing clinical tumor
specimens, but also provide insight into possible rea-
sons for the failure to isolate or expand autologous
tumor-reactive TIL from patients with melanoma.
Results
Patients
Between 2001 and 2009, melanoma samples from 39
patients with melanoma enrolled in a cancer immuno-
therapy research study approved by the Providence
Portland Medical Center’s (PPMC) Institutional Review
Board, were used to generate TIL. Signed informed
consent was obtained from all patients. Tumor specimen
from 3 patients were excluded from our study, 2 of them
are contaminated due to the site from which they were
resected, and 1 was not able to be tested for tumor-
reactivity because autologous tumor was unavailable.
Surgical specimens for immunohistochemistry studies
were obtained from the PPMC Pathology Department.
Formalin-fixed-paraffin-embedded (FFPE) specimens
and frozen section controls frozen section controls
(FSC) samples from the same date were retrieved from
Pathology for a subset of the patients whose tumors
were resected at PPMC. FSC samples were prepared by
thawing the frozen samples in OCT medium, fixing in
10 % formalin, and subsequently processed and embedded
at PPMC pathology. In some cases, these reprocessed
cryopreserved tumors were not useful for multispectral
imaging and were excluded from our multispectral
studies. Patient demographics are shown in Table 1. The
median age was 56, with a range between 23 and 79; 65 %
of the patients were male.
Comparison of methods to isolate and culture
tumor-infiltrating lymphocytes
The recent regulatory concerns regarding the source of
enzymes used for enzymatic digestion of tumors may
have led to an increased reliance on fragment cultures of
tumor samples at cancer centers investigating TIL ther-
apy. Fragment culture methods are faster and more cost
effective and studies have reviewed the efficiency of frag-
ment culture and enzymatic digest on different tumors
[13]. However we are unaware of any head-to-head
comparison of TIL generation from fragments and
enzymatic digests of the same tumor. In this report, we
compared the efficiency of fragment culture and enzym-
atic digestion in the generation of autologous tumor-
reactive TIL cultures in 13 patients. A summary of
results from this comparison is shown in Fig. 1. To
generate TIL a minimum of 12 wells of a 24 well culture
plate were initiated; 6 wells contained enzymatically
Table 1 Patient characteristics
Mel number Sex Successful expansion (N = 29) Tumor-reactive (N = 21) FFPE (N = 17) Site Time to growth (days)
Mel-119 M No Right Groin
Mel-120 F No
Mel-131 M Yes Yes Right Back 29
Mel-133 M Yes Yes FFPE Liver 30
Mel-134 M Yes Yes 38
Mel-135 F No FFPE Right supraclavicular mass
Mel-140 F Yes No 37
Mel-144 M No FFPE Intraperitoneal mass
Mel-145 M Yes Yes 27
Mel-150 F No Right back mass
Mel-160 F Yes Yes FFPE Right Thigh 26
Mel-163 A F Yes Yes FFPE Illiac LN 55
Mel-173-C 5 F Yes Yes FSC 40
Mel-176 M Yes Yes FFPE lower left lobe 34
Mel-177A F Yes Yes FSC Right Leg mass 25
Mel-179 F Yes No FSC Right axillary mass 56
Mel-180A M Yes Yes Axillary tumor mass 40
Mel-181 F Yes Yes 12
Mel-182 M No FFPE Left pelvic mass
Mel-185 M Yes Yes FSC Superior medistinal mass 33
Mel-186 M No FSC Right lower lobe mass
Mel-187 M Yes No Paracenthesis fluid 67
Mel-188 M Yes No FFPE Right Axillary LN 41
Mel-189 M No Left Chest wall
Mel-189A M Yes Yes 32
Mel-190 M No FFPE Small Bowl
Mel-191 M Yes No LN 28
Mel-192 F No Thigh
Mel-193 F No Left Lung Upper Lobe
Mel-199 M Yes Yes FSC 48
Mel-200 M Yes Yes FSC Left lower tumor 37
Mel-201 M Yes Yes 26
Mel-206 M Yes Yes 56
Mel-207 M Yes Yes 35
Mel-208 M Yes Yes Left lower lobe LN 33
Mel-209 M Yes Yes FFPE Liver mass 29
Mel-211 F Yes Yes Liver mass 26
Tumor specificity is determined by IFN-γ release when stimulated with the autologous tumor cell line or tumor digest (defined as IFN-γ release greater than
100 pg/ml and double the background (T cells alone). FFPE or FSC (frozen section control) samples are available where indicated. The letters (A, B, C) after Mel-#
designate tumors from different sites
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tumor fragments. Culture efficiency was evaluated in
two ways. First, we determined the percentage of wells
where it was possible to grow cultures of lymphocytes.
Second, we evaluated whether the lymphocytes thatgrew out exhibited autologous tumor-reactive function,
as defined by >100 pg/mL IFNγ release when stimulated
with autologous tumor and at least two times the back-
ground of T cells cultured alone. While the ability to
expand lymphocytes from tumors appeared equivalent
Fig. 1 Efficiency of TIL Generation using tumor fragment and enzymatic digest. a-b Percentage of plated wells that grew TILs for (a) each patient
and (b) average for all 13 patients. c-d Percentage of plated wells that grew tumor-reactive TILs for (c) each patient and (d) average of all 13 patients.
Statistics are established using paired parametric analysis. M: tumor fragments; E: Enzymatic digest
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methods, there was a trend towards superiority for
growth of autologous tumor-reactive lymphocytes with
enzymatic digestion (P = 0.09). Importantly, we failed to
generate autologous tumor-reactive TIL from 3 patients
(23 %) using tumor fragment culture, and from 3 patients
(23 %) when enzymatic digestion was used (Fig. 1c). If
both methods were used to generate TIL, the success rate
of generating an autologous tumor-reactive TIL culture
improved to 92 % (12/13). While the numbers are small,
this suggests that including both fragment culture and
enzymatic digestion may enhance the success of tumor-
reactive TIL isolation.
Predicting the ability to generate autologous
tumor-reactive TIL
We were able to culture autologous tumor-reactive TIL
from 21/36 (58 %) of patients. This number is similar
but a bit lower than the percentage of autologous
tumor-reactive T cells generated from a large ACT
clinical trial for treatment of melanoma (57/82, 70 %)
[26]. The schematic for our culturing conditions is
shown in Additional file 1: Figure S1. The patients from
whose tumor we could not culture TIL were retested
using cryopreserved tumor digest and the failure to grow
TIL was confirmed. The first question we asked about
the tumors from which TIL could not be grown waswhether they were infiltrated by low numbers of CD8+ T
cells. To address this question, we were able to retrieve
11 FFPE and 6 FSC blocks from our 36-patient cohort.
Two blocks (Mel-179, Mel-188) represent cases which
TIL could be successfully cultured but were not tumor-
reactive; we included these in our study and they are
highlighted in the figures for distinction. H&E sections
from selected patients were blindly reviewed by a board-
certified hematopathologist (C.B.B.) at our institute.
Lymphocytic infiltrate within the tumor was classified as
low (1+), intermediate (2+), or high (3+). No correlation
was noticed between extent of lymphocytic infiltrate and
the ability to generate TIL from the tumors (Additional
file 1: Figure S2). From this we hypothesized that the
tumor microenvironment in some patients is immuno-
suppressive such that the ability to culture TIL is lim-
ited. To address this question and further confirm our
initial finding, we utilized a multispectral quantitative
immunohistochemistry platform (Vectra, PerkinElmer,
Hopkinton, MA) to more quantitatively assess the
immune infiltrate of the tumors. Four representative
images are shown in Fig. 2; there were two distinct pat-
terns of immune infiltrate observed in our cohort: the
patients with extensive immune infiltrates (Fig. 2a, b)
and those with limited immune infiltrate (Fig. 2c, d).
Supporting our initial observation with in Additional
file 1: Figure S2, the extent of immune infiltrate alone
Fig. 2 Sample 7-plex Images. Patients with high (Top) and low (Bottom) immune infiltrate from whom TIL did not (Left) or did (Right) grow.
Images are 9 (Top) or 4 (Bottom) 200x fields stitched together for the specified melanoma specimens (a-d)
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(Fig. 3). We next examined specific immune markers
for their ability to predict generation of TIL. We found
that enumeration of the CD3+ and CD8+ T cell infil-
trates alone is insufficient to predict successful gener-
ation of TIL. Representative images of tumors from two
patients are shown in Fig. 3; although both tumors have
high CD3+ (magenta) and CD8+ (yellow) T cell infil-
trate, we were unable to culture TIL from the tumor on
the left, while we were able to generate TIL from the
tumor on the right.
Considering the failure to generate TIL may be a
consequence of an immune-suppressive environment,
we evaluated tumors for the number of CD3+FoxP3+
regulatory T cells, and CD163+ alternatively activated
(M2) macrophages; and also quantified the number of
cells expressing PD-L1. As PD-L1 can also be expressed
on melanoma cells (Additional file 1: Figure S4A), we
used a cocktail consisting of HMB45, Mart-1 and Tyro-
sinase to identify tumor cells. The cocktail was positive
in 70 % of the patients in our cohort. Since PD-L1 can also
be expressed on CD163+ macrophages, and CD3+CD8+ T
cells (Additional file 1: Figure S4B-C), we included their
expression in our evaluation as well. We analyzed the per-
cent of CD3+FoxP3+ regulatory T cells, percent of CD163+
macrophages, and PD-L1 expression using H-Score, a
value based both on the intensity of the PD-L1 expression
on a 0-3+ scale, and the number of cells that are positivefor PD-L1. We did not find any significant correlation
between the amount of CD3+FoxP3+ regulatory T
cells and the ability to generate TIL. However, when
we evaluated the relative proportion of CD8+ and
CD3+FoxP3+ regulatory T cells, we found that the ra-
tio was highly significant (P = 0.006, PPV = 91 %) in
predicting TIL culture success (Fig. 4b). This suggests
that the percent of regulatory T cells present in the
tumor may be a determining factor in limiting the
proliferation of T cells in vitro. PD-L1 expression by
itself did not correlate with the ability to culture TIL,
however, when we took the ratio of CD8+ T cells to
PD-L1+ cells, there was an increased trend(P = 0.09)
(Fig. 4c-d), suggesting a potential contributory im-
munosuppressive roles for PD-L1 in preventing the
generation of TIL in vitro. We also found an inverse
correlation between the number of CD163+ macro-
phages and the ability to culture TIL (P = 0.03). This
correlation, was however not further improved when
the number of CD8+ T cells was taken into account
(Fig. 4e-f ). We then constructed a heat map using all
available data sets (Additional file 1: Figure S7) and
performed an unsupervised hierarchical analysis on all
samples (Fig. 5). We found that the CD8+ to PD-L1+ ratio
was able to further enhance the NPV of CD8+ to FoxP3+
ratio from 86 to 100 %. Neither positive nor negative
predictive values were further improved by the
amount of CD163+ infiltrate.
Fig. 3 CD3 and CD8 are insufficient in predicting ability to generate TILs. Top: Pseudocolor H&E image of two example patients with similar CD3+ and
CD8+ T cell infiltrate. Bottom: a-b) Quantification of the total percent of CD3+ and CD8+ T cells. Red colored dots indicated tumor sample that grew
TIL but did not react to autologous tumor
Fig. 4 CD8 to FoxP3 ratio is predictive of ability to culture autologous TILs. a-b FoxP3 alone and CD8:FoxP3 ratio. c-d) PD-L1 alone and CD8:PD-L1
ratio. e-f) CD163 alone and CD8:CD163 ratio. Statistics are done with unpaired nonparametric T test (Mann–Whitney Ranked Comparison). Significance
is established at P < 0.05. Red colored dots indicated tumor sample that grew TIL but did not react to autologous tumor
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Fig. 5 Unsupervised hierarchical clustering of CD8+:FoxP3+ and CD8+:PD-L1+ ratios. The color is a continuing spectrum with dark red indicating
max expression and dark blue indicating minimum expression. *Indicates patients from whom we failed to culture TIL. **Indicates tumor sample
that grew TIL but did not react to autologous tumor
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Adoptive T cell therapy using autologous T cells has
been shown to be an effective way to treat some patients
with melanoma. The infrastructure and laboratory
support required is quite substantial and has limited TIL
therapy to a small number of academic sites. A further
limitation is that the success rate for production of
tumor-reactive TIL in melanoma has been between 50
and 70 %. Thus this therapy is currently limited to a
subset of patients with melanoma from whom tumor-
reactive TIL can be isolated and expanded. Methods that
improve the success rate of culturing tumor-reactive TIL
might increase the availability of ACT to more patients
with melanoma, and perhaps other malignancies. The
two standard methods of processing tumor for TIL
generation are culture of tumor fragments and enzymatic
digestion of tumor fragments with culture of the isolated
tumor cell suspension. We have compared both methods
for their efficiency in generating tumor-reactive TIL using
fragment culture and enzymatic digestion and found a
trend favoring increased efficiency using enzymatic digest.Importantly, we found that regardless of the method
there was a failure to produce clinically useful T cells
for adoptive immunotherapy in one of every three pa-
tients. Our data suggest that employing both methods
increased the chances for success and could maximize
the number of patients from whom TIL can be grown.
In addition, time in culture seemed to play an import-
ant role, as previously reported [27]. We found an
inverse correlation between the autologous tumor-
reactivity of TIL and the amount time they had spent
in culture (Additional file 1: Figure S4).
The second main aim of our study was to analyze the
tumor microenvironment for factors that may limit the
generation of tumor-reactive TIL. We utilized a novel
multispectral immunohistochemistry method employing
the PerkinElmer Vectra platform to examine the micro-
environment of melanoma. Part of our aim was to test
the feasibility of this method to analyze multiple markers
on a single 4-micron section of a FFPE tumor sample.
Overall, we found that the method was reproducible and
permitted the simultaneous detection of up to 7 markers
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two different methods for image analysis and found no
significant difference between using the percentage of
immune infiltrate or the number of immune infiltrating
cells per mm2 (Additional file 1: Figure S3A). We found
no significant difference in the results of the immune infil-
trate analysis whether we used the PerkinElmer inform
software or the Definiens Tissue Studio (Additional file 1:
Figure S3B). The method works best with FFPE samples,
which we could retrieve from 11 patients. For frozen
sections that are subsequently fixed with formalin, certain
markers such as CD8 can demonstrate an artifactual
punctate pattern of positivity (Additional file 1: Figure
S6F, black arrows), which increased the difficulty of the
digital morphometric analysis. We also found that FoxP3
staining in frozen sections had a higher background and
can lead to over-estimation of the number of FoxP3+ cells
due to artifacts (Additional file 1: Figure S6I, black ar-
rows). Since the artifacts are not CD3+, this problem was
circumvented in our study by using both CD3 and FoxP3
to determine the number of regulatory T cells and includ-
ing only the cells that were positive for both CD3 and
FoxP3 (Additional file 1: Figure S6I, red arrows). Detec-
tion of CD163, CD3 and PD-L1 did not seem to be af-
fected to the same degree by artifactual changes induced
by freezing (Additional file 1: Figure S6B, C, E). Detection
of melanoma cells by the melanoma cocktail was only
positive in 70 % of specimens. An alternative approach to
improve detection may be the use of an antibody against
SOX10, which has shown superior sensitivity and specifi-
city over the melanoma cocktail [28].
From our multispectral analysis, we found that the
presence of CD8+ T cells alone was insufficient in pre-
dicting the success of generating a TIL culture, while the
ratio of CD8+ T cells to CD3+FoxP3+ regulatory T cells
was a significant predictor (P = 0.006). This is consistent
with previous reports in preclinical models showing that
depletion of FoxP3+ regulatory T cells, or inhibiting
regulatory T cell function through OX40 or GITR activa-
tion, can lead to an increased CD8: Foxp3+ T cell ratios
that correlated with improved CD8+ T cell function and
therapeutic efficacy [29–31]. In other studies, regulatory
T cells isolated from tumor were shown to directly
inhibit T cell function in non-small cell lung cancer [32],
and may negatively influence the response rate of
patients receiving ACT [33, 34]. We also found that the
number of CD163+ macrophages inversely correlated
with the ability to culture TIL (Fig. 4e); consistent with
reports suggesting depletion of macrophages through
inhibition of CSF1R signaling inhibition can enhance
CD8+ T cell function in preclinical models [35–37]. This
has led to a phase I clinical trial evaluating anti-CSF-1R
administration, which identified partial clinical responses
in 5/7 patients with diffuse-type giant cell tumor [38].We evaluated the effect of arginase I and iNOS inhib-
ition during the generation of TIL cultures but found no
significant increase in recovery success (Puri et al.
manuscript in preparation). Recently, other have shown
that by using an agonist 4-1BB antibody during the
initialing of culture increased the numbers of memory
CD8+ TIL that were specific for autologous tumor and
represents a promising approach to increase the number
of patients eligible to receive adoptive immunotherapy
with TIL [39].
While PD-L1 expression by itself is not an indicator
of TIL culture success, the ratio of CD8+ T cells to
PD-L1+ cells is trending towards a significant separ-
ation, suggesting this important negative feedback
loop may limit the ability to grow tumor-reactive TIL
ex vivo. We subsequently performed unsupervised
clustering of the data, which allowed us to further
analyze the large amount of information generated
with multispectral imaging. From this analysis, we
were able to incorporate 2 out of 3 suppressive
markers from our panel and identify a cluster of pa-
tients whose tumor demonstrated both low CD8
+:FoxP3+ and low CD8+:PD-L1+ ratios (Fig. 5); and
we failed to generate TIL from these tumors. Our ob-
servations raised the question whether CD8+ T cell
proliferation was suppressed during culture, or
whether they were already anergic and unable to pro-
liferate at the time they were placed in culture due to
pre-existing suppressive mechanisms. Evidence from
murine and human studies suggests that expression of
PD-L1 and the presence FoxP3+ regulatory T cells
can reduce the anti-tumor effect of ACT [33, 34, 40, 41].
These studies imply that regulatory T cell depletion and
use of anti-PD-L1 antibody before culture may in-
crease the success rate in growing tumor-reactive TIL,
and potentially expand the use of ACT to greater
number of patients with melanoma and potentially
other malignancies.
Checkpoint blockade therapy is one of the most prom-
ising treatments for patients with solid tumors. Recent
studies suggest that the response to agents such as anti-
PD-1 and anti-PD-L1 is limited to patients with pre-
existing immune response [16, 17]. We consider the
ability to culture tumor-reactive lymphocytes from tu-
mors of patients to be a very specific indicator of a pre-
existing anti-cancer immune response. The density of
CD8+ T cells has shown to be a powerful marker in
predicting response to anti-PD-1 therapy in a small
cohort of patients, correctly predicting 13/15 patients
who are treated with anti-PD-1 therapy [16]. It is possible
that including FoxP3+ regulatory T cells may further
increase the prediction for anti-PD-1 response. We plan
to apply our multispectral immunohistochemical analysis
to patients receiving T-cell checkpoint antibodies.
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In summary, this is the first study to apply 7-color
multispectral immunohistochemistry to analyze the im-
mune environment of tumors from patients with melan-
oma. Enumeration of staining with objective assessment
software and analysis of the data using unsupervised
hierarchical clustering identified tumors where we were
unable to generate TIL. These results could be evaluated
with a prospective study to determine if this immune
profile could select patients for successful TIL gener-
ation. Additionally, since this biomarker profile appears
to identify presence of tumor-reactive T cells, it may rep-
resent a predictive biomarker of patients who will re-
spond to checkpoint blockade. While application of this
methodology is at an early stage, we consider that its
greatest promise will be as a means to identify resistance
mechanisms operational at the tumor site. In this era of
combination immunotherapy, this information will be a




Tumor procurement and processing: All tumors were
resected as part of an IRB-approved protocol of the
Providence Portland Medical Center and were numbered
sequentially upon arrival in the Human Applications
Laboratory (HAL) of the Earle A. Chiles Research Institute
(EACRI). Appropriate consent were collected from pa-
tients from whom the tumors were collected for research
use. At the beginning of these studies, all tumors were
processed by triple enzyme digestion using a mixture of
collagenase type IV (Cat# C-5138, SIGMA), hyaluronidase
type-V (Cat# H-6254, SIGMA) and deoxyribonuclease-1
(Cat# D-5025, SIGMA). Subsequently, tumors were proc-
essed using GMP manufactured enzymes that included
Liberase MTF C/T, a combination of collagenase and
thermolysin (Cat# 05339880529, Roche), Hylenex (Baxter)
or Amphadase (Amphaster), and DNase-1 recombinant
grade-1 (Cat# 04536282001, Roche). The freshly minced
tumor suspension and enzyme mixture was subsequently
mixed at room temperature for 4 to 18 h, using a
magnetic stir bar and stir plate with rotations set at the
lowest speed that would keep the tumor fragments sus-
pended. The resulting tumor digest was filtered
through a 200 micron nylon membrane and washed
twice with HBSS, counted and resuspended in Human
AB culture medium. Human AB culture medium (CM)
is comprised of RPMI 1640 (Lonza,Walkersville,MD),
25 mmol/L HEPES pH 7.2 (Lonza), L-Glutamine
(200 mM) (Lonza), penicillin/streptomycin 10,000 units/ml
(Lonza), gentamicin 50 mg/mL (Cambrex), 5.5 × 10 − 5 M
β-mercaptoethanol (Life Technologies, Eugene,OR), supple-
mented with 10 % heat-inactivated human AB serum(Valley Biomedical, Inc, Winchester, VA; Cat #HP1022; Lot
numbers K-61552, G-81460 and B-90211). These lots of
human AB serum were screened by the Surgery Branch,
NCI, NIH and shown to support generation of human TIL
(Screening information supplied by Dr. Maria Parhkurst
and Linda Parker).
For the head-to-head comparison of TIL generation
from tumor fragments and enzymatic digests, the
same tumor specimen was minced into 1–2 mm2
fragments and representative fragments were taken to
set up fragment TIL cultures. The remainder of the
minced tumor was processed for isolation of cells by
enzymatic digestion.
Briefly, TIL generation was performed similarly to that
outlined by Surgery Branch, NCI, NIH, tiltum protocol 9-
6-05 (provided by DR. John Wunderlich). Typically, at
least 6 wells of tumor fragments and 6 wells enzymatically
digested tumor were plated for culture. For tumor frag-
ment cultures, typically 4 to 10 fragments were plated into
each well of a 24 well plate containing 2 mL human AB
CM supplemented with 1000 cU/mL. Enzyme digested
tumor suspensions were adjusted to 5.0 × 105/mL in
human AB CM supplemented with 1000 cU/ml IL-2
and 2mls were plated per well of a 24 well plate. The
24 well plates were placed in a humidified 37 °C
incubator with 5 % CO2 and cultured until lympho-
cyte growth was evident. Each well of the plate was
inspected on alternate days using a low-power
inverted microscope to monitor the extrusion and
proliferation of lymphocytes. Whether or not lympho-
cyte growth was visible, half of the medium was replaced
in all wells no later than 1 week after culture initiation.
Typically, about 1 to 2 weeks after culture initiation, a
dense lymphocytic carpet would cover a portion of the
plate surrounding each fragment. When any well became
almost confluent, all the growing lymphocytes were mixed
vigorously, split into two daughter wells and filled to 2 mL
per well with CM plus 1000 cU/mL IL-2. Subsequently,
the cultures were split to maintain a cell density of 0.5 to
1.0 × 106 cells/mL, or half of the media was replaced at
least twice weekly or (as needed). The age of TIL cultures
used in these studies varied from 12 to 67 days. Each cul-
ture originating from each of the initial 6 wells plated for
each condition were considered to be an independent TIL
culture or “cloid” and maintained in a separate plate with
separate pipettes used to maintain integrity of each cloid
during expansion.
Cytokine release assays (IFNγ Release)
Tumor specificity or reactivity assays were initiated the
same day cells were harvested and frozen for future
use. TIL activity and specificity were determined by
analysis of IFNγ secretion following stimulation with
autologous tumor cells. TIL (1 × 106 cells/well) were
Feng et al. Journal for ImmunoTherapy of Cancer  (2015) 3:47 Page 10 of 11plated in a 24-well plate with 2.5 × 105 autologous
stimulator tumor cells/well. Autologous tumor cells
were either cryopreserved enzymatic tumor digests or au-
tologous melanoma cell lines. Control wells contained ei-
ther TIL alone or tumor cells alone. Supernatants were
harvested after 18–20 h and IFNγ secretion was measured
by enzymes linked-immunosorbent assay (ELISA) tech-
nique according to manufacturers guidelines (eBioscience)
TIL. were considered autologous tumor-reactive if at least
one of the TIL cloids released >100 pg/ml of IFNγ and this
value was > twice the background values (IFNγ release
from TIL alone).Immunohistochemistry
4 μm thick sections were prepared and stained using
PerkinElmer Opal kit. Slides were scanned using the
PerkinElmer Vectra and images were analyzed using the
inForm software (PerkinElmer, Hopkinton, MA). The
rabbit anti-human CD8 monoclonal antibody (SP239,
M5394 Spring Biosciences) and anti-human CD163
monoclonal antibody (MRQ26, 760–4437, Ventana) were
both kind gifts of Ms. Alisa Tubbs (Ventana, Tucson, AZ).
For a detailed protocol see “Additional file 2”.Statistical analysis
Significance between groups are established using un-
paired T test performed in Graphpad Prism. Unsupervised
hierarchical analysis is performed using TIBCO Spotfire,
UPGMA clustering method.Additional files
Additional file 1: Figure S1. Schematic representation of process for
TIL initiation, expansion and testing. Figure S2. Lymphocytic immune
infiltrate is insufficient to predict TIL culture success. A) Representative
H&E stain from 4 patients, two are classified as 3+ (Top) and two are
classified as 1+ (Bottom), TIL culture status is indicated above images. B)
Compares average pathology scores of lymphocytic infiltrate between
tumors that grew TILs and those that did not. Figure S3. Comparison of
two methods to evaluate immune infiltrate. A) Comparison between %
CD8 T cell infiltrate and # of CD8 positive cells/mm^2. B) Comparison
between # of CD8 positive T cells/mm^2 determined using PerkinElmer
and Definiens. The comparisons were done using the identical image.
Statistics were determined using Prism. Figure S4. PD-L1 Localization. A)
On tumor cells B) on CD8+ T cells and C) on CD163+ macrophages.
Figure S5. Time of growth is predictive of tumor reactivity. Statistics were
done using unpaired nonparametric T test. Significance was established
at P < 0.05. Figure S6. Comparison between FFPE (Top) and frozen
(Bottom) sections. A,F) CD8; B,G) CD3; C,H) CD163; D,I) FoxP3; E,J) PD-L1.
Figure S7. Heatmap representation of parameters generated from
multispectral imaging with dark red indicating maximal expression and
dark blue indicating minimum expression. *indicates patients from
whom we failed to culture TIL. **indicates tumor sample that grew TIL
that were not reactive to autologous tumor. Figure S8. Multispectral
image showing individual channels: Original is the raw image with all
channels taken using the Vectra imaging software. The spectrum for
each fluorophore is measured with control slides and subtracted from
the original image to establish individual channels and the composite.
Figure S9. Representative image from individual multispectral samples.TIL status is indicated with “+” or “-“. Enumerated immune infiltrates are
indicated for each sample in the lower right corner. (PPTX 38563 kb)
Additional file 2: Supplemental methods. Detailed
immunohistochemistry methods for multispectral analysis. (DOCX 20 kb)
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